Immunogenicity and Safety of the M72/AS01(E) Candidate Vaccine Against Tuberculosis: A Meta-Analysis

Background: Currently, there is no tuberculosis (TB) vaccine recommended for use in latent TB infections and healthy adults. M72/AS01(E) is a new peptide vaccine currently under development, which may improve protection against TB disease. This vaccine has been investigated in several phase I/II cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Zhenhua, Jian, Miaomiao, Chen, Taigui, Luo, Lisha, Li, Lianbao, Dai, Xiting, Bai, Ruolan, Ding, Zhe, Bi, Yunfeng, Wen, Shiyuan, Zhou, Guozhong, Abi, Manzama-Esso, Liu, Aihua, Bao, Fukai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735267/
https://www.ncbi.nlm.nih.gov/pubmed/31552037
http://dx.doi.org/10.3389/fimmu.2019.02089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735267/
https://www.ncbi.nlm.nih.gov/pubmed/31552037
http://dx.doi.org/10.3389/fimmu.2019.02089

Ejemplares similares